Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 157

1.

A Pilot Study of Changes in Medial Temporal Lobe Fractional Amplitude of Low Frequency Fluctuations after Sildenafil Administration in Patients with Alzheimer's Disease.

Samudra N, Motes M, Lu H, Sheng M, Diaz-Arrastia R, Devous M, Hart J, Womack KB.

J Alzheimers Dis. 2019 May 25. doi: 10.3233/JAD-190128. [Epub ahead of print]

PMID:
31156166
2.

A multicentre longitudinal study of flortaucipir (18F) in normal ageing, mild cognitive impairment and Alzheimer's disease dementia.

Pontecorvo MJ, Devous MD, Kennedy I, Navitsky M, Lu M, Galante N, Salloway S, Doraiswamy PM, Southekal S, Arora AK, McGeehan A, Lim NC, Xiong H, Truocchio SP, Joshi AD, Shcherbinin S, Teske B, Fleisher AS, Mintun MA.

Brain. 2019 Jun 1;142(6):1723-1735. doi: 10.1093/brain/awz090.

3.

Tau Positron-Emission Tomography in Former National Football League Players.

Stern RA, Adler CH, Chen K, Navitsky M, Luo J, Dodick DW, Alosco ML, Tripodis Y, Goradia DD, Martin B, Mastroeni D, Fritts NG, Jarnagin J, Devous MD Sr, Mintun MA, Pontecorvo MJ, Shenton ME, Reiman EM.

N Engl J Med. 2019 May 2;380(18):1716-1725. doi: 10.1056/NEJMoa1900757. Epub 2019 Apr 10.

PMID:
30969506
4.

Parametric methods for [18F]flortaucipir PET.

Golla SS, Wolters EE, Timmers T, Ossenkoppele R, van der Weijden CW, Scheltens P, Schwarte L, Mintun MA, Devous MD Sr, Schuit RC, Windhorst AD, Lammertsma AA, Yaqub M, van Berckel BN, Boellaard R.

J Cereb Blood Flow Metab. 2018 Dec 20:271678X18820765. doi: 10.1177/0271678X18820765. [Epub ahead of print]

PMID:
30569813
5.

Standardization of amyloid quantitation with florbetapir standardized uptake value ratios to the Centiloid scale.

Navitsky M, Joshi AD, Kennedy I, Klunk WE, Rowe CC, Wong DF, Pontecorvo MJ, Mintun MA, Devous MD Sr.

Alzheimers Dement. 2018 Dec;14(12):1565-1571. doi: 10.1016/j.jalz.2018.06.1353. Epub 2018 Jul 11.

PMID:
30006100
6.

Topographic staging of tau positron emission tomography images.

Schwarz AJ, Shcherbinin S, Slieker LJ, Risacher SL, Charil A, Irizarry MC, Fleisher AS, Southekal S, Joshi AD, Devous MD Sr, Miller BB, Saykin AJ; Alzheimer's Disease Neuroimaging Initiative.

Alzheimers Dement (Amst). 2018 Feb 14;10:221-231. doi: 10.1016/j.dadm.2018.01.006. eCollection 2018.

7.

Test-Retest Reproducibility for the Tau PET Imaging Agent Flortaucipir F 18.

Devous MD Sr, Joshi AD, Navitsky M, Southekal S, Pontecorvo MJ, Shen H, Lu M, Shankle WR, Seibyl JP, Marek K, Mintun MA.

J Nucl Med. 2018 Jun;59(6):937-943. doi: 10.2967/jnumed.117.200691. Epub 2017 Dec 28.

8.

Flortaucipir F 18 Quantitation Using Parametric Estimation of Reference Signal Intensity.

Southekal S, Devous MD Sr, Kennedy I, Navitsky M, Lu M, Joshi AD, Pontecorvo MJ, Mintun MA.

J Nucl Med. 2018 Jun;59(6):944-951. doi: 10.2967/jnumed.117.200006. Epub 2017 Nov 30.

9.

Sildenafil Improves Vascular and Metabolic Function in Patients with Alzheimer's Disease.

Sheng M, Lu H, Liu P, Li Y, Ravi H, Peng SL, Diaz-Arrastia R, Devous MD, Womack KB.

J Alzheimers Dis. 2017;60(4):1351-1364. doi: 10.3233/JAD-161006.

10.

18 F-flortaucipir tau positron emission tomography distinguishes established progressive supranuclear palsy from controls and Parkinson disease: A multicenter study.

Schonhaut DR, McMillan CT, Spina S, Dickerson BC, Siderowf A, Devous MD Sr, Tsai R, Winer J, Russell DS, Litvan I, Roberson ED, Seeley WW, Grinberg LT, Kramer JH, Miller BL, Pressman P, Nasrallah I, Baker SL, Gomperts SN, Johnson KA, Grossman M, Jagust WJ, Boxer AL, Rabinovici GD.

Ann Neurol. 2017 Oct;82(4):622-634. doi: 10.1002/ana.25060.

11.

Effectiveness of Florbetapir PET Imaging in Changing Patient Management.

Pontecorvo MJ, Siderowf A, Dubois B, Doraiswamy PM, Frisoni GB, Grundman M, Nobili F, Sadowsky CH, Salloway S, Arora AK, Chevrette A, Deberdt W, Dell'Agnello G, Flitter M, Galante N, Lowrey MJ, Lu M, McGeehan A, Devous MD Sr, Mintun MA.

Dement Geriatr Cogn Disord. 2017;44(3-4):129-143. doi: 10.1159/000478007. Epub 2017 Aug 5.

12.

Correlation between two methods of florbetapir PET quantitative analysis.

Breault C, Piper J, Joshi AD, Pirozzi SD, Nelson AS, Lu M, Pontecorvo MJ, Mintun MA, Devous MD.

Am J Nucl Med Mol Imaging. 2017 Jul 15;7(3):84-91. eCollection 2017.

13.

Association of Longitudinal Cognitive Decline With Amyloid Burden in Middle-aged and Older Adults: Evidence for a Dose-Response Relationship.

Farrell ME, Kennedy KM, Rodrigue KM, Wig G, Bischof GN, Rieck JR, Chen X, Festini SB, Devous MD Sr, Park DC.

JAMA Neurol. 2017 Jul 1;74(7):830-838. doi: 10.1001/jamaneurol.2017.0892.

14.

Quantification of Tau Load Using [18F]AV1451 PET.

Golla SSV, Timmers T, Ossenkoppele R, Groot C, Verfaillie S, Scheltens P, van der Flier WM, Schwarte L, Mintun MA, Devous M, Schuit RC, Windhorst AD, Lammertsma AA, Boellaard R, van Berckel BNM, Yaqub M.

Mol Imaging Biol. 2017 Dec;19(6):963-971. doi: 10.1007/s11307-017-1080-z.

15.

Use of white matter reference regions for detection of change in florbetapir positron emission tomography from completed phase 3 solanezumab trials.

Fleisher AS, Joshi AD, Sundell KL, Chen YF, Kollack-Walker S, Lu M, Chen S, Devous MD Sr, Seibyl J, Marek K, Siemers ER, Mintun MA.

Alzheimers Dement. 2017 Oct;13(10):1117-1124. doi: 10.1016/j.jalz.2017.02.009. Epub 2017 Mar 30.

PMID:
28365320
16.

Relationships between flortaucipir PET tau binding and amyloid burden, clinical diagnosis, age and cognition.

Pontecorvo MJ, Devous MD Sr, Navitsky M, Lu M, Salloway S, Schaerf FW, Jennings D, Arora AK, McGeehan A, Lim NC, Xiong H, Joshi AD, Siderowf A, Mintun MA; 18F-AV-1451-A05 investigators.

Brain. 2017 Mar 1;140(3):748-763. doi: 10.1093/brain/aww334.

17.

Quantitation of PET signal as an adjunct to visual interpretation of florbetapir imaging.

Pontecorvo MJ, Arora AK, Devine M, Lu M, Galante N, Siderowf A, Devadanam C, Joshi AD, Heun SL, Teske BF, Truocchio SP, Krautkramer M, Devous MD Sr, Mintun MA.

Eur J Nucl Med Mol Imaging. 2017 May;44(5):825-837. doi: 10.1007/s00259-016-3601-4. Epub 2017 Jan 7.

PMID:
28064343
18.

Amyloid deposition in younger adults is linked to episodic memory performance.

Bischof GN, Rodrigue KM, Kennedy KM, Devous MD Sr, Park DC.

Neurology. 2016 Dec 13;87(24):2562-2566. Epub 2016 Nov 11.

19.

Successful classification of cocaine dependence using brain imaging: a generalizable machine learning approach.

Mete M, Sakoglu U, Spence JS, Devous MD Sr, Harris TS, Adinoff B.

BMC Bioinformatics. 2016 Oct 6;17(Suppl 13):357.

20.

Revolutionizing Alzheimer's disease and clinical trials through biomarkers.

Mattsson N, Carrillo MC, Dean RA, Devous MD Sr, Nikolcheva T, Pesini P, Salter H, Potter WZ, Sperling RS, Bateman RJ, Bain LJ, Liu E.

Alzheimers Dement (Amst). 2015 Oct 3;1(4):412-9. doi: 10.1016/j.dadm.2015.09.001. eCollection 2015 Dec. Review.

21.

Kinetics of the Tau PET Tracer 18F-AV-1451 (T807) in Subjects with Normal Cognitive Function, Mild Cognitive Impairment, and Alzheimer Disease.

Shcherbinin S, Schwarz AJ, Joshi A, Navitsky M, Flitter M, Shankle WR, Devous MD Sr, Mintun MA.

J Nucl Med. 2016 Oct;57(10):1535-1542. Epub 2016 May 5.

22.

Dopamine efflux in response to ultraviolet radiation in addicted sunbed users.

Aubert PM, Seibyl JP, Price JL, Harris TS, Filbey FM, Jacobe H, Devous MD Sr, Adinoff B.

Psychiatry Res Neuroimaging. 2016 May 30;251:7-14. doi: 10.1016/j.pscychresns.2016.04.001. Epub 2016 Apr 7.

23.

Regional profiles of the candidate tau PET ligand 18F-AV-1451 recapitulate key features of Braak histopathological stages.

Schwarz AJ, Yu P, Miller BB, Shcherbinin S, Dickson J, Navitsky M, Joshi AD, Devous MD Sr, Mintun MS.

Brain. 2016 May;139(Pt 5):1539-50. doi: 10.1093/brain/aww023. Epub 2016 Mar 2.

PMID:
26936940
24.

Double-blind, placebo-controlled, proof-of-concept trial of bexarotene Xin moderate Alzheimer's disease.

Cummings JL, Zhong K, Kinney JW, Heaney C, Moll-Tudla J, Joshi A, Pontecorvo M, Devous M, Tang A, Bena J.

Alzheimers Res Ther. 2016 Jan 29;8:4. doi: 10.1186/s13195-016-0173-2.

25.

Bridging the Gap between Research and Clinical Practice in Asymptomatic Alzheimer's Disease.

Downing AM, Yaari R, Ball DE, Selzler KJ, Devous MD Sr.

J Prev Alzheimers Dis. 2016;3(1):30-42. doi: 10.14283/jpad.2015.86.

PMID:
29214279
26.

A Semiautomated Method for Quantification of F 18 Florbetapir PET Images.

Joshi AD, Pontecorvo MJ, Lu M, Skovronsky DM, Mintun MA, Devous MD Sr.

J Nucl Med. 2015 Nov;56(11):1736-41. doi: 10.2967/jnumed.114.153494. Epub 2015 Sep 3.

27.

Technical Considerations in Brain Amyloid PET Imaging with 18F-Florbetapir.

Trembath L, Newell M, Devous MD Sr.

J Nucl Med Technol. 2015 Sep;43(3):175-84. doi: 10.2967/jnmt.115.156679. Epub 2015 Aug 13. Review.

28.

The effect of beta-amyloid on face processing in young and old adults: A multivariate analysis of the BOLD signal.

Rieck JR, Rodrigue KM, Kennedy KM, Devous MD Sr, Park DC.

Hum Brain Mapp. 2015 Jul;36(7):2514-26. doi: 10.1002/hbm.22788. Epub 2015 Apr 2.

29.

Quantification of 18F-florbetapir PET: comparison of two analysis methods.

Hutton C, Declerck J, Mintun MA, Pontecorvo MJ, Devous MD Sr, Joshi AD; Alzheimer’s Disease Neuroimaging Initiative.

Eur J Nucl Med Mol Imaging. 2015 Apr;42(5):725-32. doi: 10.1007/s00259-015-2988-7. Epub 2015 Feb 5.

PMID:
25652817
30.

The Centiloid Project: standardizing quantitative amyloid plaque estimation by PET.

Klunk WE, Koeppe RA, Price JC, Benzinger TL, Devous MD Sr, Jagust WJ, Johnson KA, Mathis CA, Minhas D, Pontecorvo MJ, Rowe CC, Skovronsky DM, Mintun MA.

Alzheimers Dement. 2015 Jan;11(1):1-15.e1-4. doi: 10.1016/j.jalz.2014.07.003. Epub 2014 Oct 28.

31.

Interaction between early life stress and alcohol dependence on neural stress reactivity.

Yang H, Spence JS, Briggs RW, Rao U, North C, Devous MD Sr, Xiao H, Adinoff B.

Addict Biol. 2015 May;20(3):523-33. doi: 10.1111/adb.12135. Epub 2014 Mar 7.

32.

Cortico-amygdala coupling as a marker of early relapse risk in cocaine-addicted individuals.

McHugh MJ, Demers CH, Salmeron BJ, Devous MD Sr, Stein EA, Adinoff B.

Front Psychiatry. 2014 Feb 27;5:16. doi: 10.3389/fpsyt.2014.00016. eCollection 2014.

33.

Altered neural processing of threat in alcohol-dependent men.

Yang H, Devous MD, Briggs RW, Spence JS, Xiao H, Kreyling N, Adinoff B.

Alcohol Clin Exp Res. 2013 Dec;37(12):2029-38. doi: 10.1111/acer.12187. Epub 2013 Jul 24.

34.

Risk factors for mild cognitive impairment among Mexican Americans.

O'Bryant SE, Johnson L, Reisch J, Edwards M, Hall J, Barber R, Devous MD Sr, Royall D, Singh M.

Alzheimers Dement. 2013 Nov;9(6):622-631.e1. doi: 10.1016/j.jalz.2012.12.007. Epub 2013 May 2.

35.

Risk factors for β-amyloid deposition in healthy aging: vascular and genetic effects.

Rodrigue KM, Rieck JR, Kennedy KM, Devous MD Sr, Diaz-Arrastia R, Park DC.

JAMA Neurol. 2013 May;70(5):600-6. doi: 10.1001/jamaneurol.2013.1342.

36.

Biomarkers of Alzheimer's disease among Mexican Americans.

O'Bryant SE, Xiao G, Edwards M, Devous M, Gupta VB, Martins R, Zhang F, Barber R; Texas Alzheimer's Research and Care Consortium (TARCC).

J Alzheimers Dis. 2013;34(4):841-9. doi: 10.3233/JAD-122074.

37.

The link between C-reactive protein and Alzheimer's disease among Mexican Americans.

O'Bryant SE, Johnson L, Edwards M, Soares H, Devous MD, Ross S, Rohlfing G, Hall J; Texas Alzheimer’s Research & Care Consortium.

J Alzheimers Dis. 2013;34(3):701-6. doi: 10.3233/JAD-122071.

38.

Striatal-limbic activation is associated with intensity of anticipatory anxiety.

Yang H, Spence JS, Devous MD Sr, Briggs RW, Goyal A, Xiao H, Yadav H, Adinoff B.

Psychiatry Res. 2012 Nov 30;204(2-3):123-31. doi: 10.1016/j.pscychresns.2012.10.001. Epub 2012 Nov 6.

39.

Characterization of Mexican Americans with mild cognitive impairment and Alzheimer's disease.

O'Bryant SE, Johnson L, Balldin V, Edwards M, Barber R, Williams B, Devous M, Cushings B, Knebl J, Hall J.

J Alzheimers Dis. 2013;33(2):373-9. doi: 10.3233/JAD-2012-121420.

40.
41.

Effects of beta-amyloid accumulation on neural function during encoding across the adult lifespan.

Kennedy KM, Rodrigue KM, Devous MD Sr, Hebrank AC, Bischof GN, Park DC.

Neuroimage. 2012 Aug 1;62(1):1-8. doi: 10.1016/j.neuroimage.2012.03.077. Epub 2012 May 1.

42.

Differences in regional cerebral blood flow response to a 5HT3 antagonist in early- and late-onset cocaine-dependent subjects.

Adinoff B, Devous MD, Williams MJ, Harris TS, Best SE, Dong H, Zielinski T.

Addict Biol. 2014 Mar;19(2):250-61. doi: 10.1111/j.1369-1600.2012.00450.x. Epub 2012 Mar 28.

43.

Association of common genetic variants in GPCPD1 with scaling of visual cortical surface area in humans.

Bakken TE, Roddey JC, Djurovic S, Akshoomoff N, Amaral DG, Bloss CS, Casey BJ, Chang L, Ernst TM, Gruen JR, Jernigan TL, Kaufmann WE, Kenet T, Kennedy DN, Kuperman JM, Murray SS, Sowell ER, Rimol LM, Mattingsdal M, Melle I, Agartz I, Andreassen OA, Schork NJ, Dale AM; Alzheimer's Disease Neuroimaging Initiative; Pediatric Imaging, Neurocognition, and Genetics Study, Weiner M, Aisen P, Petersen R, Jack CR Jr, Jagust W, Trojanowki JQ, Toga AW, Beckett L, Green RC, Saykin AJ, Morris J, Liu E, Montine T, Gamst A, Thomas RG, Donohue M, Walter S, Gessert D, Sather T, Harvey D, Kornak J, Dale A, Bernstein M, Felmlee J, Fox N, Thompson P, Schuff N, Alexander G, DeCarli C, Bandy D, Koeppe RA, Foster N, Reiman EM, Chen K, Mathis C, Cairns NJ, Taylor-Reinwald L, Trojanowki JQ, Shaw L, Lee VM, Korecka M, Crawford K, Neu S, Foroud TM, Potkin S, Shen L, Kachaturian Z, Frank R, Snyder PJ, Molchan S, Kaye J, Quinn J, Lind B, Dolen S, Schneider LS, Pawluczyk S, Spann BM, Brewer J, Vanderswag H, Heidebrink JL, Lord JL, Johnson K, Doody RS, Villanueva-Meyer J, Chowdhury M, Stern Y, Honig LS, Bell KL, Morris JC, Ances B, Carroll M, Leon S, Mintun MA, Schneider S, Marson D, Griffith R, Clark D, Grossman H, Mitsis E, Romirowsky A, deToledo-Morrell L, Shah RC, Duara R, Varon D, Roberts P, Albert M, Onyike C, Kielb S, Rusinek H, de Leon MJ, Glodzik L, De Santi S, Doraiswamy PM, Petrella JR, Coleman RE, Arnold SE, Karlawish JH, Wolk D, Smith CD, Jicha G, Hardy P, Lopez OL, Oakley M, Simpson DM, Porsteinsson AP, Goldstein BS, Martin K, Makino KM, Ismail MS, Brand C, Mulnard RA, Thai G, Mc-Adams-Ortiz C, Womack K, Mathews D, Quiceno M, Diaz-Arrastia R, King R, Weiner M, Martin-Cook K, DeVous M, Levey AI, Lah JJ, Cellar JS, Burns JM, Anderson HS, Swerdlow RH, Apostolova L, Lu PH, Bartzokis G, Silverman DH, Graff-Radford NR, Parfitt F, Johnson H, Farlow MR, Hake AM, Matthews BR, Herring S, van Dyck CH, Carson RE, MacAvoy MG, Chertkow H, Bergman H, Hosein C, Black S, Stefanovic B, Caldwell C, Ging-Yuek, Hsiung R, Feldman H, Mudge B, Assaly M, Kertesz A, Rogers J, Trost D, Bernick C, Munic D, Kerwin D, Mesulam MM, Lipowski K, Wu CK, Johnson N, Sadowsky C, Martinez W, Villena T, Turner RS, Johnson K, Reynolds B, Sperling RA, Johnson KA, Marshall G, Frey M, Yesavage J, Taylor JL, Lane B, Rosen A, Tinklenberg J, Sabbagh M, Belden C, Jacobson S, Kowall N, Killiany R, Budson AE, Norbash A, Johnson PL, Obisesan TO, Wolday S, Bwayo SK, Lerner A, Hudson L, Ogrocki P, Fletcher E, Carmichael O, Olichney J, Kittur S, Borrie M, Lee TY, Bartha R, Johnson S, Asthana S, Carlsson CM, Potkin SG, Preda A, Nguyen D, Tariot P, Fleisher A, Reeder S, Bates V, Capote H, Rainka M, Scharre DW, Kataki M, Zimmerman EA, Celmins D, Brown AD, Pearlson GD, Blank K, Anderson K, Santulli RB, Schwartz ES, Sink KM, Williamson JD, Garg P, Watkins F, Ott BR, Querfurth H, Tremont G, Salloway S, Malloy P, Correia S, Rosen HJ, Miller BL, Mintzer J, Longmire CF, Spicer K, Finger E, Rachinsky I, Drost D, Jernigan T, McCabe C, Grant E, Ernst T, Kuperman J, Chung Y, Murray S, Bloss C, Darst B, Pritchett L, Saito A, Amaral D, DiNino M, Eyngorina B, Sowell E, Houston S, Soderberg L, Kaufmann W, van Zijl P, Rizzo-Busack H, Javid M, Mehta N, Ruberry E, Powers A, Rosen B, Gebhard N, Manigan H, Frazier J, Kennedy D, Yakutis L, Hill M, Gruen J, Bosson-Heenan J, Carlson H.

Proc Natl Acad Sci U S A. 2012 Mar 6;109(10):3985-90. doi: 10.1073/pnas.1105829109. Epub 2012 Feb 16.

44.

β-Amyloid burden in healthy aging: regional distribution and cognitive consequences.

Rodrigue KM, Kennedy KM, Devous MD Sr, Rieck JR, Hebrank AC, Diaz-Arrastia R, Mathews D, Park DC.

Neurology. 2012 Feb 7;78(6):387-95. doi: 10.1212/WNL.0b013e318245d295. Epub 2012 Feb 1.

45.

A comprehensive reliability assessment of quantitative diffusion tensor tractography.

Wang JY, Abdi H, Bakhadirov K, Diaz-Arrastia R, Devous MD Sr.

Neuroimage. 2012 Apr 2;60(2):1127-38. doi: 10.1016/j.neuroimage.2011.12.062. Epub 2011 Dec 29.

46.

Comparison of relative cerebral blood flow maps using pseudo-continuous arterial spin labeling and single photon emission computed tomography.

Liu P, Uh J, Devous MD, Adinoff B, Lu H.

NMR Biomed. 2012 May;25(5):779-86. doi: 10.1002/nbm.1792. Epub 2011 Dec 2.

47.

Caudolateral orbitofrontal regional cerebral blood flow is decreased in abstinent cocaine-addicted subjects in two separate cohorts.

Adinoff B, Braud J, Devous MD, Harris TS.

Addict Biol. 2012 Nov;17(6):1001-12. doi: 10.1111/j.1369-1600.2011.00414.x. Epub 2011 Nov 29.

48.

Distinctive disruption patterns of white matter tracts in Alzheimer's disease with full diffusion tensor characterization.

Huang H, Fan X, Weiner M, Martin-Cook K, Xiao G, Davis J, Devous M, Rosenberg R, Diaz-Arrastia R.

Neurobiol Aging. 2012 Sep;33(9):2029-45. doi: 10.1016/j.neurobiolaging.2011.06.027. Epub 2011 Aug 27.

49.

Longitudinal changes of structural connectivity in traumatic axonal injury.

Wang JY, Bakhadirov K, Abdi H, Devous MD Sr, Marquez de la Plata CD, Moore C, Madden CJ, Diaz-Arrastia R.

Neurology. 2011 Aug 30;77(9):818-26. doi: 10.1212/WNL.0b013e31822c61d7. Epub 2011 Aug 3.

50.

Activation of the mesostriatal reward pathway with exposure to ultraviolet radiation (UVR) vs. sham UVR in frequent tanners: a pilot study.

Harrington CR, Beswick TC, Graves M, Jacobe HT, Harris TS, Kourosh S, Devous MD Sr, Adinoff B.

Addict Biol. 2012 May;17(3):680-6. doi: 10.1111/j.1369-1600.2010.00312.x. Epub 2011 Apr 11.

PMID:
21481104

Supplemental Content

Loading ...
Support Center